A Phase I, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of SN2001 in Healthy Adult Subjects
Latest Information Update: 24 Jul 2025
At a glance
- Drugs SN 2001 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
Most Recent Events
- 24 Jul 2025 New trial record